CYP4A22 catalyzes the omega-and (omega-1)-hydroxylation of various fatty acids such as laurate and palmitate. It shows no activity towards arachidonic acid and prostaglandin A1. This protein lacks functional activity in the kidney and does not contribute to renal 20-hydroxyeicosatetraenoic acid (20-HETE) biosynthesis.
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Target:
The synthetic peptide sequence used to generate the antibody AP8785a was selected from the N-term region of human CYP4A22. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
* VAT and and shipping costs not included. Errors and price changes excepted
